Gonadorelin: A GnRH Decapeptide for Pituitary-Gonadal Axis Stimulation

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to gonadorelin. Gonadorelin is not FDA-approved for any current indication in a commercially available product. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

When the FDA effectively ended access to compounded hCG in March 2020, physicians who use it to preserve testicular function in men on testosterone replacement therapy needed an alternative. Compounded gonadorelin emerged as the primary substitute — a synthetic copy of the hormone that sits one step upstream of hCG in the signaling chain. Whether that substitution is clinically equivalent is a question the published literature has not fully resolved, and the answer depends heavily on dosing frequency, delivery method, and what outcome you are trying to achieve.

Here is what gonadorelin is, how its mechanism differs from hCG, what the clinical evidence actually shows, and what the regulatory history means for patients considering it today.

Key Takeaways

• Regulatory Status: As of April 2026, no FDA-approved gonadorelin product is commercially available in the United States. The original branded product Factrel (gonadorelin hydrochloride injection, Wyeth) was withdrawn from the market; no active NDA or ANDA for gonadorelin is currently approved. Compounded gonadorelin is available through licensed compounding pharmacies where permitted.
• Research Stage: Established clinical evidence in pulsatile pump therapy for congenital hypogonadotropic hypogonadism (CHH); limited direct trial data for compounded gonadorelin as a TRT adjunct
• Availability: Available only through licensed compounding pharmacies by prescription; Superpower Health does not offer gonadorelin
• What it is: A synthetic decapeptide identical to endogenous GnRH, studied for pituitary gonadotropin stimulation and testicular function maintenance.
• What the evidence actually shows: Pulsatile gonadorelin effectively stimulates LH and FSH in men with CHH; direct evidence for its use as a TRT adjunct remains limited as of April 2026.
• Compound reference: PubChem CID 638793

Where Gonadorelin Comes From and How It Works

Origin and discovery

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a ten-amino-acid peptide produced by specialized neurons in the hypothalamus. GnRH was first characterized in 1971 by Roger Guillemin and Andrew Schally, work that earned them the Nobel Prize in Physiology or Medicine in 1977. The endogenous hormone is released in discrete pulses into the hypothalamic-pituitary portal circulation, where it reaches the anterior pituitary and stimulates the synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Gonadorelin (the synthetic analog) has an amino acid sequence identical to native human GnRH and was developed to replicate this physiological signal for therapeutic purposes. Santoro, Filicori, Spratt, and Crowley reviewed the clinical physiology of GnRH in men and women in Acta Medica Hungarica in 1986, consolidating early pulse-analysis work from the Crowley group into a coherent picture of how hypothalamic pulse frequency and amplitude shape pituitary output across the reproductive lifespan.

The pulsatile mechanism and why it is non-negotiable

The single most important pharmacological fact about gonadorelin is that its biological effect is inseparable from the pattern of its delivery. The physiological basis for this was established in men before the Knobil work: Santen and Bardin in a 1973 paper in the Journal of Clinical Investigation, used frequent blood sampling to document that LH in adult men is secreted in discrete episodic pulses rather than as a continuous output, providing the direct human evidence that endogenous gonadotropin release is a pulsatile process. A landmark 1978 study by Belchetz, Plant, Nakai, Keogh, and Knobil, published in Science, then demonstrated in rhesus monkeys that intermittent pulsatile GnRH administration is required to sustain gonadotropin secretion, while continuous infusion of the same total dose causes pituitary desensitization and suppression of LH and FSH. This is not a dosing preference — it is a receptor-level consequence of how GnRH receptors on pituitary gonadotroph cells become downregulated when continuously occupied. The clinical implication is direct: a continuous subcutaneous infusion of gonadorelin at a stable rate would suppress the very gonadotropins it is meant to stimulate. This is the pharmacological basis for the GnRH agonist class of drugs (leuprolide, goserelin) used in prostate cancer therapy, which work precisely by desensitizing the pituitary. Gonadorelin used therapeutically must mimic the natural hypothalamic pulse pattern — typically at approximately 90-minute intervals — to sustain gonadotropin secretion.

Pharmacokinetics: a two-to-eight-minute half-life

A 1986 review by Handelsman and Swerdloff in Endocrine Reviews documented the pharmacokinetics of native GnRH and its analogs, establishing that gonadorelin has a plasma half-life of approximately two to eight minutes following intravenous administration. This extremely short half-life reflects rapid enzymatic degradation by endopeptidases in the portal circulation and peripheral tissues. The practical consequence for subcutaneous dosing — the route used in most compounding protocols — is that the compound is cleared rapidly, which theoretically allows for pulsatile receptor stimulation with minimal inter-dose accumulation. However, subcutaneous absorption is slower and more variable than intravenous delivery, which complicates the assumption that subcutaneous injections faithfully replicate the discrete hypothalamic pulse pattern that drives physiological gonadotropin release.

The HPG axis: where gonadorelin acts

Gonadorelin acts at the first link in the hypothalamic-pituitary-gonadal (HPG) axis — the hypothalamic GnRH pulse generator, which drives the entire downstream cascade. A 2018 authoritative review by Herbison in Endocrinology described the hypothalamic GnRH pulse generator and its regulation by KNDy neurons (kisspeptin/neurokinin B/dynorphin), which control the timing and amplitude of GnRH pulses. When gonadorelin is delivered in physiologically appropriate pulses, it stimulates pituitary gonadotroph cells to release LH and FSH. LH then acts on Leydig cells in the testes to stimulate testosterone biosynthesis, while FSH acts on Sertoli cells to support spermatogenesis. This is one step upstream of hCG, which bypasses the pituitary entirely and acts directly on the LH receptor in gonadal tissue.

What the Clinical Evidence Shows

Established efficacy in hypogonadotropic hypogonadism

The strongest clinical evidence for pulsatile GnRH therapy comes from patients with congenital hypogonadotropic hypogonadism (CHH) — a condition in which GnRH secretion is absent or severely impaired from birth, resulting in failure of pubertal development and persistent hypogonadism. In this population, the pituitary is intact and responsive; the problem is the absent upstream GnRH signal. Replacing that signal with pulsatile gonadorelin or GnRH pump therapy directly addresses the pathological deficit. An earlier controlled comparison by Kliesch, Behre, and Nieschlag, published in the European Journal of Endocrinology in 1994, established the high efficacy of pulsatile GnRH and gonadotropin therapy for inducing spermatogenesis in hypogonadotropic men and helped anchor pulsatile GnRH as a first-line fertility induction strategy in this population. A 1998 study by Büchter, Behre, Kliesch, and Nieschlag in European Journal of Endocrinology reviewed 42 men with hypogonadotropic hypogonadism treated with either pulsatile GnRH or hCG/hMG combination therapy and found both approaches effective for inducing spermatogenesis, with comparable sperm output. A 2020 systematic review and meta-analysis by Wei, Long, Zhang, and colleagues in World Journal of Men's Health pooled eight comparative studies (seven cohorts, 420 men) evaluating pulsatile GnRH versus combined gonadotropin therapy for spermatogenesis in CHH and reported that pulsatile GnRH achieved earlier onset of spermatogenesis and fewer estradiol-related adverse reactions, although overall spermatogenesis rate, sperm concentration, and pregnancy rate did not differ significantly between the two approaches. A contemporary 2025 head-to-head comparison by Zheng, Bai, and colleagues in Reproductive Biology and Endocrinology confirmed that pulsatile GnRH remains effective in CHH with comparable or superior fertility outcomes versus combined gonadotropin therapy.

The clinical framework around this evidence base is codified in consensus documents. Boehm, Bouloux, Dattani, and colleagues published a European Consensus Statement on CHH in Nature Reviews Endocrinology in 2015, outlining diagnostic criteria and treatment algorithms that include pulsatile GnRH as a standard fertility induction option alongside combined gonadotropin therapy. Young, Xu, Papadakis, and colleagues provided a comprehensive clinical management review of CHH in Endocrine Reviews in 2019, consolidating evidence on gonadorelin pump therapy indications, dose titration, monitoring, and expected response curves. These guideline-level references locate pulsatile gonadorelin within an established standard of care for a specific clinical population, distinct from the off-label TRT-adjunct context discussed below.

Pulsatile GnRH also retains clinical utility beyond classical CHH. Huang, Mao, and colleagues, writing in Endocrine Practice in 2022, compared pulsatile GnRH responses in pituitary stalk interruption syndrome versus CHH and documented that patients with stalk interruption can achieve meaningful gonadotropin and testosterone responses, though with a different trajectory than isolated GnRH deficiency. A further 2024 study by Huang, Wang, and colleagues in Archives of Endocrinology and Metabolism examined pulsatile GnRH as rescue therapy in CHH patients who had responded poorly to combined gonadotropin therapy, reporting meaningful spermatogenic response in a subset of non-responders and suggesting pulsatile GnRH may be useful as a second-line strategy before fertility induction is abandoned.

Predictors of outcome and duration of therapy

A 2002 study by Pitteloud, Hayes, Boepple, and colleagues in the Journal of Clinical Endocrinology and Metabolism followed 76 men with idiopathic hypogonadotropic hypogonadism on pulsatile GnRH therapy for 12–24 months, stratified by prior pubertal development: 52 with absent prior puberty (40% with a history of cryptorchidism), 18 with partial prior puberty (5% cryptorchid), and 6 with adult-onset disease. Men with partial or complete prior puberty achieved sperm in the ejaculate in 100% of cases, whereas only 82% of the absent-prior-puberty group produced any sperm, with a median sperm count of 3 × 10⁶/mL — well below the fertile range. In multivariable analysis, prior pubertal development (p = 0.003), baseline inhibin B ≥ 60 pg/mL (p = 0.009), and absence of cryptorchidism (p = 0.05) independently predicted spermatogenic response. A 2024 comprehensive review by Dwyer, McDonald, and Quinton in the Annals of the New York Academy of Sciences summarized the current framework for fertility induction in men with CHH, noting that pulsatile GnRH and combined gonadotropin therapy are both established options with comparable overall efficacy, with pulsatile GnRH preferred when the goal is to most closely replicate physiological HPG axis function.

The question of how long therapy needs to continue is complicated by the observation that a subset of CHH is not permanent. Raivio, Falardeau, Dwyer, and colleagues in a 2007 paper in the New England Journal of Medicine, reported reversal of idiopathic hypogonadotropic hypogonadism in a meaningful fraction of patients after discontinuation of therapy, implying that endogenous GnRH pulse generator function can recover in some individuals. That finding informs decisions about trial discontinuation and reinforces the importance of objective biochemical monitoring rather than indefinite therapy by default.

Use in women with hypothalamic amenorrhea

Pulsatile GnRH therapy has a well-established clinical application in women with functional hypothalamic amenorrhea (FHA) and hypothalamic hypogonadotropic hypogonadism — conditions in which GnRH pulse frequency is suppressed by energy deficit, exercise, psychological stress, or idiopathic causes. A 1993 study by Martin, Hall, Adams, and Crowley in the Journal of Clinical Endocrinology and Metabolism demonstrated lower multiple-pregnancy and ovarian hyperstimulation syndrome (OHSS) risk with pulsatile GnRH compared to exogenous gonadotropin therapy for ovulation induction in women with hypogonadotropic amenorrhea, reflecting the more physiological, predominantly monofollicular stimulation pattern. A 25-year cohort study by Quaas, Quaas, Fischer, and colleagues in the Journal of Assisted Reproduction and Genetics, published in 2022, documented a high cumulative live-birth rate in women with FHA treated with pulsatile GnRH pump, with near-exclusively monofollicular ovulation and a favorable safety profile over the observation period. A 2025 comparative study by Everaere, Simon, Bachelot, and colleagues in Fertility and Sterility extended this evidence by directly comparing pulsatile GnRH pump efficacy in functional hypothalamic amenorrhea versus congenital hypogonadotropic hypogonadism, reporting comparable ongoing pregnancy rates per initiated cycle (21.5% in FHA versus 22% in CHH) and predominantly monofollicular ovulation across both groups, supporting pulsatile GnRH as an appropriate ovulation-induction strategy across the spectrum of hypothalamic hypogonadism. These data support pulsatile GnRH as a physiological alternative to gonadotropin therapy in women with hypothalamic hypogonadotropic hypogonadism, though this application requires pump-based delivery with carefully programmed pulse intervals.

The evidence gap: compounded gonadorelin as a TRT adjunct

The clinical evidence summarized above refers to pump-delivered pulsatile GnRH therapy for diagnosed hypogonadotropic conditions — not to subcutaneous injections of compounded gonadorelin as an adjunct to exogenous testosterone replacement therapy. This distinction matters. The use of compounded gonadorelin to preserve testicular function or spermatogenesis in men receiving TRT is an extrapolation from the CHH data, not a directly studied indication with its own controlled trials. When compounded hCG became legally unavailable after the FDA's March 2020 enforcement action against compounded hCG preparations, clinicians sought alternatives. Compounded gonadorelin became the most widely used substitute, as noted in a 2025 review by Hochu and colleagues in Translational Andrology and Urology that addressed preserving spermatogenesis in testosterone deficiency and the hCG supply shift. However, the clinical trial base supporting gonadorelin specifically for this TRT-adjunct indication is limited as of April 2026. Providers using it in this context are applying mechanistic reasoning — gonadorelin stimulates LH and FSH, which hCG also stimulates at the gonadal receptor level — to fill a gap where direct evidence is sparse.

Gonadorelin vs. hCG: Key Differences

Gonadorelin and hCG address the same clinical problem — maintaining testicular function and spermatogenesis in men on testosterone therapy — but through mechanisms separated by one step in the signaling cascade. This comparison is for scientific context only. These compounds have fundamentally different regulatory statuses and evidence bases, and neither has an FDA-approved indication specifically for use as a TRT adjunct.

hCG acts directly on the LH/hCG receptor in Leydig cells, bypassing the pituitary entirely. It delivers the downstream gonadotropin signal without requiring a functional anterior pituitary. A foundational 2005 randomized dose-response study by Coviello, Matsumoto, Bremner, and colleagues in the Journal of Clinical Endocrinology and Metabolism randomized 29 healthy men to testosterone enanthate 200 mg weekly plus either placebo or hCG at 125, 250, or 500 IU every other day for three weeks, with intratesticular testosterone measured by fine-needle aspiration. Placebo-group intratesticular testosterone collapsed by 94% (from 1,234 to 72 nmol/L), while 125 IU preserved it at 25% below baseline, 250 IU at 7% below baseline, and 500 IU actually pushed it 26% above baseline, with a linear dose-response relationship (p < 0.001). A 2013 retrospective review by Hsieh, Pastuszak, Hwang, and Lipshultz in the Journal of Urology followed 26 hypogonadal men (mean age 35.9 years) on testosterone replacement with concomitant hCG 500 IU intramuscularly every other day over a mean follow-up of 6.2 months (extending beyond 1 year in a subset); no patient became azoospermic, pretreatment sperm density of 35.2 million/mL was preserved with no significant change during follow-up, and 9 of 26 men (35%) contributed to a pregnancy — a contrast with the approximately 40% azoospermia rate historically observed on testosterone monotherapy. The retrospective, uncontrolled design limits causal inference. Wenker, Dupree, Langille, and colleagues in a 2015 Journal of Sexual Medicine retrospective two-center chart review, followed 49 men with azoospermia or severe oligospermia (<1 million/mL) while on exogenous testosterone and treated with hCG 3,000 IU subcutaneously every other day plus a physician-selected adjunct (clomiphene, tamoxifen, anastrozole, or recombinant FSH); 47 of 49 men (95.9%) recovered sperm production with a mean time to recovery of 4.6 months and a mean initial post-recovery density of 22.6 million/mL, with no discontinuations for adverse events. The retrospective, non-randomized design and heterogeneous adjunct therapy limit causal attribution to hCG alone. These studies represent the evidentiary foundation for hCG as a TRT adjunct — a body of clinical evidence that gonadorelin, in its compounded injectable form, does not yet match.

Broader reviews have placed these options within the clinician's decision tree. Kim, Crosnoe, Bar-Chama, and colleagues reviewed the treatment of hypogonadism in men of reproductive age in Fertility and Sterility in 2013, laying out the role of GnRH, hCG, and selective estrogen receptor modulators as fertility-preserving alternatives to direct testosterone replacement. Lee and Ramasamy, writing in Translational Andrology and Urology in 2018, focused specifically on indications for hCG in the management of infertility in hypogonadal men, clarifying which clinical presentations make hCG (rather than testosterone replacement alone) the first-line choice. More recently, Fink, Ide, and Horie reviewed management of male fertility in hypogonadal patients on TRT in Medicina in 2024, summarizing adjunct strategies — including hCG, SERMs, and GnRH-based approaches — with direct attention to the evidence gap around compounded gonadorelin as an hCG substitute. Hashimi and colleagues in a 2025 clinician's guide in Asian Journal of Andrology, addressed the management of azoospermia induced by exogenous testosterone or anabolic-androgenic steroids, a clinical context where gonadorelin use has expanded without a dedicated controlled trial base.

Gonadorelin, by contrast, acts at the pituitary. It requires an intact and responsive anterior pituitary to generate LH and FSH. In men on exogenous testosterone, pituitary gonadotroph cells are suppressed by the negative feedback of circulating testosterone and its aromatized product estradiol. Whether pulsatile subcutaneous gonadorelin injections can overcome this suppression and generate sufficient LH to maintain intratesticular testosterone is the central unanswered pharmacological question. The two-to-eight-minute plasma half-life further complicates subcutaneous dosing: the absorption curve from a subcutaneous injection does not replicate the sharp discrete pulse of endogenous GnRH, and the pituitary's response to a blunted, slowly absorbed signal may differ from its response to an acute pulse. A 2025 review by Naelitz, Momtazi-Mar, Lundy, and colleagues in Nature Reviews Urology addressed testosterone replacement therapy and spermatogenesis in reproductive-age men and noted that while gonadorelin represents a theoretical alternative to hCG, the clinical evidence base requires further development before definitive efficacy comparisons can be drawn.

Regulatory and Legal Status

FDA classification and the Factrel withdrawal

As of April 2026, no FDA-approved gonadorelin product is available on the US market. The branded product Factrel (gonadorelin hydrochloride injection, 100 mcg/mL and 500 mcg/mL, manufactured by Wyeth) was previously FDA-approved for diagnostic testing of pituitary-gonadotroph function and was used clinically for this indication. Factrel was withdrawn from the market by the manufacturer — not by FDA enforcement action — and no equivalent approved product has been brought to market to replace it. The withdrawal means there is no active FDA-approved labeling, no DailyMed prescribing information, and no reference product against which compounded formulations are evaluated. Compounded gonadorelin is prepared by licensed 503A compounding pharmacies under state pharmacy board oversight and is not equivalent to an FDA-approved drug product.

Compounding pharmacy context

With no approved reference product, compounded gonadorelin occupies an unusual regulatory position. It is not classified as a Category 2 bulk drug substance under the FDA's 503B outsourcing facility framework (which would prohibit it from compounding), but neither is it manufactured under the quality standards and clinical evidence requirements of FDA drug approval. As a result, the purity, sterility, potency, and clinical pharmacology of compounded gonadorelin formulations vary by pharmacy and are not subject to FDA manufacturing oversight. This is not a theoretical concern: independent testing of compounded peptide products has found inconsistencies in labeled versus actual content. Patients obtaining compounded gonadorelin through legitimate licensed pharmacies have materially different risk profiles than those obtaining products from unregulated online vendors, but neither route provides the quality assurance of an FDA-approved product.

Sport ban status

As of the 2026 WADA Prohibited List, GnRH and its analogs — including gonadorelin — are prohibited under category S2 (peptide hormones, growth factors, related substances, and mimetics) both in and out of competition. Athletes subject to anti-doping rules should treat gonadorelin as a prohibited substance regardless of the clinical context in which it is used.

What this means practically

Gonadorelin is not available as an FDA-approved prescription product. It can be obtained through a licensed 503A compounding pharmacy with a valid prescription from a licensed provider. Products sold online without a prescription and without pharmacy oversight are unregulated, lack quality controls, and may not contain what they claim. There is no legal pathway to obtain pharmaceutical-grade, FDA-approved gonadorelin for human use in the United States as of April 2026. Any clinical use represents the independent judgment of the prescribing provider, not an FDA-approved indication.

Safety: What Is and Is Not Known

Absence of clinical safety data for the TRT-adjunct indication

The safety profile of pulsatile GnRH pump therapy in CHH has been characterized over decades of clinical use for that specific indication and population. The safety of compounded subcutaneous gonadorelin injections in men on testosterone therapy has not been systematically studied in controlled trials as of April 2026. The two contexts are pharmacologically distinct: in CHH, gonadorelin is the only source of gonadotropin stimulation in a patient with absent baseline HPG function; in men on TRT, it is administered into a hormonal environment already altered by exogenous testosterone and its consequences. We do not know the side effect profile, optimal dosing frequency, or long-term safety parameters of compounded gonadorelin in the TRT-adjunct context specifically.

Risks from unregulated sources

As discussed, compounded gonadorelin from unregulated online vendors lacks quality controls for sterility, potency, and identity. Contamination risk, dosing inconsistency, and the presence of degradation products are documented concerns across the broader category of compounded peptide products. Even from licensed compounding pharmacies, the absence of FDA manufacturing oversight means lot-to-lot variability is a realistic concern. Patients using compounded gonadorelin should obtain it exclusively through a licensed pharmacy with a valid prescription.

Who Should Not Use Gonadorelin

Based on gonadorelin's proposed mechanism of action, the following groups face elevated theoretical risk or represent populations where its use would be inappropriate:

• Individuals with primary hypogonadism (testicular failure, including Klinefelter syndrome) — gonadorelin stimulates pituitary LH and FSH release but cannot compensate for a testes that cannot respond; the signal is generated but reaches a non-functional target
• Men receiving continuous GnRH agonist therapy (leuprolide, goserelin) for prostate cancer or other indications — gonadorelin would add to or complicate the intentional HPG axis suppression that is the therapeutic goal
• Individuals with active hormone-sensitive malignancies, including prostate cancer — testosterone elevation from restored gonadal function may affect disease progression
• Competitive athletes subject to WADA anti-doping rules — gonadorelin is prohibited under the 2026 WADA Prohibited List (S2: peptide hormones, growth factors, and related substances)
• Pregnant individuals — no safety data exists for this population, and GnRH signaling is central to reproductive endocrinology in ways that make exogenous administration during pregnancy inappropriate
• Individuals with known hypersensitivity to GnRH or synthetic GnRH analogs

Which Biomarkers Are Relevant if You Are Exploring Gonadorelin or HPG Axis Function?

Understanding where the HPG axis stands before and during any intervention is the practical foundation for evaluating whether gonadorelin or any related therapy is having its intended effect. The markers below are directly relevant to the signaling cascade that gonadorelin targets.

• Luteinizing hormone (LH): The immediate downstream output of GnRH stimulation at the pituitary. Low or suppressed LH in a man with low testosterone confirms secondary (central) hypogonadism and indicates a deficit in the HPG axis that gonadorelin is theoretically designed to address. Rising LH in response to gonadorelin is the direct pharmacological signal that pituitary stimulation is occurring.
• Follicle-stimulating hormone (FSH): Released alongside LH in response to GnRH pulses, FSH drives spermatogenesis through its action on Sertoli cells. Baseline FSH provides information about pituitary output and spermatogenic potential. Changes in FSH during gonadorelin therapy reflect pituitary responsiveness to GnRH stimulation.
• Total testosterone: The primary outcome marker for gonadal androgen production. In men with secondary hypogonadism, successful HPG axis stimulation should produce measurable increases in total testosterone. Establishing a pre-treatment baseline is essential for evaluating any response.
• Free testosterone: The biologically active fraction not bound to sex hormone-binding globulin or albumin. In men with elevated SHBG, total testosterone may overstate the degree of available androgen, making free testosterone an important complementary measure.
• Estradiol: Testosterone aromatizes to estradiol in peripheral tissue. Elevated estradiol contributes to negative feedback on the HPG axis and, at high levels, produces symptoms including gynecomastia and reduced libido. Monitoring estradiol during any testosterone-elevating intervention provides information about aromatization rate and helps providers assess whether estradiol management is warranted.
• Sex hormone-binding globulin (SHBG): Binds testosterone in circulation and reduces the free fraction. Elevated SHBG is common in older men and in certain metabolic states, and it significantly affects how total testosterone values should be interpreted. SHBG is necessary context for any meaningful assessment of androgenic status.
• Prolactin: Elevated prolactin independently suppresses GnRH and LH secretion and is a reversible cause of secondary hypogonadism. Ruling out hyperprolactinemia before attributing low gonadotropins to another cause prevents misdiagnosis and ensures the correct underlying problem is being addressed.

When to Take This Seriously

Reduced testicular function, low testosterone, and impaired fertility in men are real clinical problems with established, FDA-approved evaluation and treatment pathways. Endocrinologists and urologists with expertise in male reproductive medicine regularly evaluate these presentations and have access to FDA-approved therapies — including hCG (Pregnyl, Novarel, Ovidrel) and, in appropriate cases, gonadotropin therapy — with documented clinical evidence. If the clinical question is fertility preservation during testosterone use, the Endocrine Society Clinical Practice Guideline by Bhasin, Brito, Cunningham, and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 2018, explicitly addresses fertility-preserving alternatives to TRT and represents the standard of care reference. Understanding your baseline hormone panel is the appropriate starting point regardless of what intervention is being considered. Without that baseline, neither you nor your provider can evaluate whether an intervention is working.

That commitment to objective data before any clinical decision is central to Superpower's approach to preventive health: the belief that understanding your biology is the foundation for every health decision, whether you are exploring established therapies or evaluating compounds at the edge of the clinical evidence base. The testosterone, SHBG, and prolactin biomarker panel provides a starting point for understanding where the HPG axis stands before any hormonal intervention.

IMPORTANT SAFETY INFORMATION

Gonadorelin is not FDA-approved for any current indication. No FDA-approved gonadorelin product is commercially available in the United States as of April 2026. The previously approved product Factrel (gonadorelin hydrochloride injection, Wyeth) was withdrawn from the market by the manufacturer. Compounded gonadorelin is available only through licensed 503A compounding pharmacies with a valid prescription from a licensed healthcare provider. Compounded gonadorelin is not an FDA-approved drug product and has not been evaluated by the FDA for safety, efficacy, or manufacturing quality. Superpower Health does not prescribe, sell, compound, or facilitate access to gonadorelin.

Sport prohibition: As of the 2026 WADA Prohibited List, gonadorelin (a GnRH analog) is prohibited in and out of competition under category S2 (peptide hormones, growth factors, related substances, and mimetics). Athletes subject to anti-doping rules should treat gonadorelin as a prohibited substance.

Do not use gonadorelin if: you have primary hypogonadism (testicular failure) or Klinefelter syndrome; you are receiving continuous GnRH agonist therapy for prostate cancer or other indications; you have an active hormone-sensitive malignancy; you have a known hypersensitivity to GnRH or synthetic GnRH analogs; or you are pregnant.

Warnings: pituitary desensitization occurs with continuous (non-pulsatile) administration and will suppress rather than stimulate gonadotropin secretion; compounded products carry risks of sterility failure, potency inconsistency, and contamination; no controlled safety data exist for use as a TRT adjunct in men; long-term safety and efficacy data for compounded gonadorelin in off-label indications are absent.

Common side effects reported with GnRH administration: injection site reactions (redness, swelling, discomfort); headache; nausea; flushing. In clinical use with pulsatile pump delivery, hypersensitivity reactions have been reported. Side effects from subcutaneous injections of compounded gonadorelin have not been systematically characterized in clinical trials.

Not available as an FDA-approved product. All compounded use represents the independent clinical judgment of the prescribing provider. Patients should verify compounding eligibility and current regulatory status with a licensed pharmacist at the time of prescribing, as regulatory classifications for compounded peptides are subject to change.

Additional Questions

What is the FDA peptide reclassification, and does it affect gonadorelin?

The FDA's February 2026 reclassification affected specific peptides designated as Category 2 bulk drug substances, prohibiting their use in compounded medications. As of April 2026, gonadorelin has not been placed on the Category 2 prohibited list and remains compoundable by licensed 503A pharmacies with a valid prescription. The broader regulatory environment for compounded peptides continues to evolve, and the status of individual compounds can change. Patients and providers should verify current compounding eligibility with a licensed pharmacy at the time of prescribing.

What biomarkers should I test to evaluate HPG axis function?

The core panel includes LH, FSH, total testosterone, estradiol, SHBG, and prolactin. LH and FSH establish where the pituitary-gonadal signaling stands — low LH alongside low testosterone indicates secondary hypogonadism, the population in which gonadorelin has theoretical relevance. Prolactin rules out hyperprolactinemia as a reversible cause. SHBG contextualizes total testosterone values. Estradiol tracks aromatization. A provider will interpret these values in the context of your clinical presentation and determine the appropriate evaluation and management path.

Why did compounded hCG become unavailable, and how does gonadorelin relate?

In March 2020, the FDA enforced restrictions that effectively ended the legal compounding of hCG, citing that hCG is a biologic (not a small-molecule drug) and that FDA-approved brand-name hCG products (Pregnyl, Novarel, Ovidrel) are commercially available. Because compounded hCG had been widely used by physicians to maintain testicular function and spermatogenesis in men on TRT, its unavailability created a clinical gap. A 2023 cross-sectional study by Borgert, Bacchus, Hernandez, and colleagues in Sexual Medicine surveyed 81 FDA-registered compounding pharmacies and found that only 5 were actively supplying gonadotropins, with 6 of 8 pharmacies that had stopped compounding hCG and FSH citing the 2020 FDA mandate as the reason — quantifying the access contraction that followed the regulatory shift from compounded to brand-name-only gonadotropin availability. Compounded gonadorelin emerged as the primary alternative — not because controlled trial evidence established it as equivalent, but because it is compoundable, mechanistically plausible, and was the most available substitute. The evidence for it as a TRT adjunct continues to develop.